These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9350014)

  • 1. Serum CA-125 measurements > 65 U/mL. Clinical value.
    Eltabbakh GH; Belinson JL; Kennedy AW; Gupta M; Webster K; Blumenson LE
    J Reprod Med; 1997 Oct; 42(10):617-24. PubMed ID: 9350014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
    Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
    Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
    Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
    Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
    Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
    Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical analysis of benign pelvic mass with high serum levels of CA(125)].
    Zhang X; Wu LY; Li XJ; Li HJ; Zhang R; Liu LY
    Zhonghua Fu Chan Ke Za Zhi; 2005 Mar; 40(3):178-82. PubMed ID: 15840313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.
    Santillan A; Garg R; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK; Bristow RE
    J Clin Oncol; 2005 Dec; 23(36):9338-43. PubMed ID: 16361633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
    Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
    Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of renal function on serum levels of CA 125.
    Menzin AW; Kobrin S; Pollak E; Goodman DB; Rubin SC
    Gynecol Oncol; 1995 Sep; 58(3):375-7. PubMed ID: 7672704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.
    Hefler L; Tempfer C; Heinze G; Mayerhofer K; Breitenecker G; Leodolter S; Reinthaller A; Kainz C
    Br J Cancer; 1999 Nov; 81(5):855-9. PubMed ID: 10555758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of serum CA 125 elevation in malignant and nonmalignant diseases.
    Sjövall K; Nilsson B; Einhorn N
    Gynecol Oncol; 2002 Apr; 85(1):175-8. PubMed ID: 11925140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign gynecologic conditions associated with a CA-125 level > 1,000 U/mL. A case report.
    Kammerer-Doak DN; Magrina JF; Nemiro JS; Lidner TK
    J Reprod Med; 1996 Mar; 41(3):179-82. PubMed ID: 8778417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of referral guidelines for women with pelvic masses.
    Im SS; Gordon AN; Buttin BM; Leath CA; Gostout BS; Shah C; Hatch KD; Wang J; Berman ML
    Obstet Gynecol; 2005 Jan; 105(1):35-41. PubMed ID: 15625139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrioid adenocarcinoma of the ovary and endometriosis.
    Valenzuela P; Ramos P; Redondo S; Cabrera Y; Alvarez I; Ruiz A
    Eur J Obstet Gynecol Reprod Biol; 2007 Sep; 134(1):83-6. PubMed ID: 16844279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
    Cane P; Azen C; Lopez E; Platt LD; Karlan BY
    Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of Ca 125 levels during primary therapy.
    Markmann S; Gerber B; Briese V
    Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids.
    Sevinc A; Buyukberber S; Sari R; Kiroglu Y; Turk HM; Ates M
    Gynecol Oncol; 2000 May; 77(2):254-7. PubMed ID: 10785474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
    Krajcik RA; Borofsky ND; Massardo S; Orentreich N
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.